Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy
Clinical trial NCT06782542 · RECRUITING
Trial details
- NCT number
- NCT06782542
- Sponsor
- Justin Watts, MD
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-31
- Primary completion
- 2029-03-31
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.